These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2016931)

  • 1. [What is the cost of hypertension treatment to society?].
    Aberg H
    Lakartidningen; 1991 Mar; 88(12):1055-6. PubMed ID: 2016931
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of hypertension in Sweden: treatment of patients with hypertension costs more than a billion crowns per year].
    Johannesson M; Borgqvist L; Jönsson B; Råstam L
    Lakartidningen; 1991 Mar; 88(12):1103-6. PubMed ID: 2016946
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of hypertension at a health center. 1: The drugs prescribed for men are much more expensive than the ones prescribed for women].
    Johannesson M; Borgquist L; Elenstål A; Jönsson B; Tilling B
    Lakartidningen; 1991 Mar; 88(12):1096-8. PubMed ID: 2016944
    [No Abstract]   [Full Text] [Related]  

  • 4. [New guidelines for the treatment of hypertension--what has really happened since the last time?].
    Hjemdahl P
    Lakartidningen; 1990 Sep; 87(39):3068-9. PubMed ID: 2215021
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fully possible to reduce the costs of hypertension treatment].
    Wettermark B; Angman A; Hjemdahl P
    Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
    [No Abstract]   [Full Text] [Related]  

  • 6. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 7. Changing prescription patterns: impact on costs.
    Bock KD
    J Hypertens Suppl; 1987 Aug; 5(3):S83-5. PubMed ID: 3478431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consumption of antihypertensive drugs and costs of treatment of arterial hypertension at a Swiss medical polyclinic (1975-1985)].
    Graf F; Knorr M; Siegenthaler W; Vetter W
    Schweiz Rundsch Med Prax; 1986 Apr; 75(14):378-84. PubMed ID: 3961350
    [No Abstract]   [Full Text] [Related]  

  • 9. [The cost of antihypertensive drug combinations].
    Buitrago F
    Med Clin (Barc); 1996 May; 106(17):677. PubMed ID: 8691916
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 12. Variability in antihypertensive drug costs.
    Kawachi I; Malcom L; Purdie G
    N Z Med J; 1989 Aug; 102(874):449. PubMed ID: 2761899
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacoeconomic aspects of the treatment of essential hypertension].
    Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
    Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
    [No Abstract]   [Full Text] [Related]  

  • 14. Roundtable discussion: Part II--Development of a pharmacoeconomic model in hypertension.
    Penna P; Cox E; Joseph T; Lehman L; Morrow T; Richter A; Sowers J; Tepper D
    Manag Care Interface; 2000; Suppl C():17-23. PubMed ID: 11183935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.
    Stafilas PC; Sarafidis PA; Lasaridis AN; Aletras VH; Niakas DA
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1233-40; discussion 1241-2. PubMed ID: 16182115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Stading JA; Stoysich AM; Ryschon K
    Clin Ther; 1994; 16(1):88-102; discussion 87. PubMed ID: 7911403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
    Johannesson M
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oil and water? Economic advantage and biomedical progress do not mix well in a government guidelines committee.
    Ménard J
    Am J Hypertens; 1994 Oct; 7(10 Pt 1):877-85. PubMed ID: 7826550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug expenditures for hypertension: an empirical test of an economic model in a French population.
    Huttin C; Avorn J
    Cah Sociol Demogr Med; 1997; 37(1):33-52. PubMed ID: 9239318
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of antihypertensive drugs in Spain (1995-2001)].
    García del Pozo J; Ramos Sevillano E; de Abajo FJ; Mateos Campos R
    Rev Esp Cardiol; 2004 Mar; 57(3):241-9. PubMed ID: 15056428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.